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Metastatic colorectal cancer represents a major health problem in the US and worldwide. 
Forty percent of patients undergoing resection of the primary tumor will experience relapse. 
In this brief review, we describe a case of a woman with metastatic disease and long-term 
survival culminating with an unusual myocardial recurrence. Over three decades, a 
multimodality approach has evolved to allow for long-term survival in selected patients with 
metastatic colorectal cancer. In this case report, the role of multiple aggressive surgical 
resections is emphasized. 
 
Introduction 
Approximately 140,000 new cases of colorectal cancer are diagnosed annually in the 
United States [1]. Approximately 70% will undergo operative management and of 
those, about 40% will experience relapse [2]. Presented is a case study of a patient with 
over 17 years long-term survival of multiply recurrent metastatic colon carcinoma. In 
these 17 years, the patient has undergone four operations for tumor recurrence 
without any other adjuvant therapy besides the chemoradiation therapy completed 
after the time of initial diagnosis, with the latest recurrence being to the myocardium. 
In this case report, we wish to emphasize the integral role of surgery for recurrent 
disease and the unusual nature of the cardiac recurrence, and explore the implications 
and limitations of these multiple surgical interventions.  
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In 1992, a 60-year-old white female presented with hematochezia and change in bowel habits. 
Evaluation revealed rectosigmoid cancer without liver metastases on CT scan. Carcinoembryonic 
antigen (CEA) level was 28.7 ng/dl. She underwent low anterior resection. Pathology demonstrated 
well-differentiated adenocarcinoma, T3N1 (stage III). The patient underwent adjuvant therapy with 
5-fluorouracil, levamisole and radiation therapy, completing therapy in 1993. 
In July 1995, a CT scan for persistently elevated CEA demonstrated a lesion in the left lobe of her 
liver. MRI confirmed the left lobe lesion and was suspicious for a right lobe lesion as well. The patient 
underwent partial left and partial right hepatectomies in October 1995. Surgical pathology 
demonstrated recurrent adenocarcinoma with negative margins in both lesions. CEA levels returned 
to within normal range postoperatively. In the fall of 1999, an office visit physical exam revealed a 
palpable mass in her old incision site from the midepigastric region to the edge of the liver. CEA levels 
were also slightly elevated. Subsequent CT scans confirmed local tumor recurrence. The patient 
underwent right rectus muscle resection with partial antrectomy for adherent tumor. Margins were 
negative and the patient had an uneventful recovery. In September 2006, 16 years since her initial 
colon cancer diagnosis, a routine CEA measurement was again slightly elevated. Repeat CT scan 
demonstrated areas of abnormality in what would be the falciform ligament and in the abdominal 
wall just right of midline. A PET scan confirmed these areas of abnormality and indicated a more 
intrahepatic source. The patient underwent en bloc wedge liver resection, partial diaphragm 
resection, partial gastrectomy and partial right chest wall resection. No surgical margins were 
involved and the patient had an uneventful recovery. 
In April 2009, the patient underwent reevaluation for elevated CEA. The heart border was 
abnormal on CT scan, and transesophageal echocardiogram showed a mass in the right 
atrioventricular groove. MRI confirmed this mass with some tumor involvement in the right atrium. 
The patient was asymptomatic. Repeat CT and PET scans at this time showed no other evidence of 
metastatic disease (fig. 1). In May 2009, the patient underwent cardiac surgery (fig. 2) and resection. 
The resection included right atrium and ventricular free wall with radical pericardectomy. Initial 
margins were involved, but were negative after additional resection. The defect was repaired with 
bovine pericardial patch, tricuspid valvuloplasty and bypass grafting. The patient had an uneventful 
recovery. A follow-up PET/CT scan 6 months after her cardiac surgery showed evidence for extension 
of the neoplastic disease in her left and right atria, confirmed by MRI. Gene markers confirmed tumor 
sensitivity to chemotherapy. The patient was started on oxaliplatin-based chemotherapy with 
bevacizumab. Last visit was November 2011 and she was on single agent bevacizumab without 
disease progression. 
Discussion 
Approximately 140,000 new cases of colorectal cancer are diagnosed annually in the 
United States [1]. According to a study of the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) database of approximately 140,000 people with 
colon cancer between 1999 and 2006, the 5-year survival rate for a stage III colon 
cancer patient is 70% [1]. The patient described in this case is now a 78-year-old 
woman with long-term survival from 17 years of recurrent colon cancer, initially stage 
III. She underwent low anterior resection with adjuvant chemoradiation therapy 
completed by 1993 and she has since undergone four more operations for metastases 
and local recurrences, including two liver resections, right chest wall and right 
abdominal wall resections, and most recently, cardiac resection. In this case, surgery 
was the best means of therapy for the recurrent disease at each time point and we 
suggest that the multiple surgical interventions are the main reason for this patient’s 
long-term survival with metastatic colon adenocarcinoma. Table 1 shows the patient’s 
course and interventions.  
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The latest curative-intent surgery undergone by this long-term colon cancer 
survivor has been cardiac resection, and this has resulted in the shortest disease-free 
interval of all her resections (6 months). There appear to be a total of ten case reports 
in the literature since 1982 of colorectal cancer metastases to the heart [3–12]. Indeed, 
the literature suggests cardiac metastasis from colorectal cancer to be extremely rare, 
probably less than 2% of all cases based on autopsy series [13, 14]. Currently, there are 
no studies investigating the role of surgery in colorectal cancer cardiac metastases. Our 
patient underwent one cardiac resection and at 6 months follow-up was shown to have 
recurrence and extension of disease on PET imaging. Chemotherapy is the treatment of 
choice as no further cardiac resection is being considered. 
When discussing colorectal cancer survival, several contributing factors are 
considered. One such factor is tumor biology, such as degree of differentiation, nodal 
involvement at presentation, CEA level, and mutations in k-ras and p53 [15]. Although 
these tumor markers are not routinely tested and the exact biology of this tumor is 
unknown, the patient likely has a less aggressive type of colon adenocarcinoma. If this 
tumor were more aggressive, recurrences would likely be widely metastatic, precluding 
further surgical intervention. As is seen in this case, however, all of her recurrences 
were either isolated metastases or resectable local recurrences, deeming surgical 
intervention appropriate therapy. 
This particular patient did not benefit from improved chemotherapy as she was 
diagnosed in 1992 and treated with levamisole, a drug no longer used. She did, 
however, benefit from surgical intervention in 1995, 1999, 2006, and 2009. The patient 
also received consistent follow-up with her surgeon and oncologist which included 
frequent CEA measurements, as well as colonoscopies, CT, MRI and PET imaging when 
necessary that proved essential in detecting early recurrence amenable to curative-
intent salvage surgery. The interesting surgical management in this case comes not at 
the onset of her disease, but throughout the multiple recurrences in the past 17 years, 
lastly the myocardial recurrence. Surgery remained the principal clinical intervention 
for this patient early on and she has benefited with long-term survival. Survival for 
stage IV colorectal cancer has been improving dramatically since 1998 for many 
reasons, including improvements in chemotherapy and more aggressive surgical 
resections [16]. At the times of this patient’s metastatic disease resections, adjuvant 
therapy after metastasectomy was not considered standard of care, and the issue 
remains controversial [17, 18]. In the past 17 years, the patient has not undergone 
adjuvant chemotherapy after resection of recurrences. However, with her current 
cardiac recurrence, the patient underwent FOLFOX with bevacizumab and after being 
reevaluated for tumor sensitivity, bevacizumab only most recently. Current salvage 
chemotherapy regimens appear to improve survival for locally and distant recurrent 
disease [19]. 
This patient is an example of long-term metastatic colon cancer survival whose 
latest recurrence is in the heart, a very unusual place for colorectal metastatic disease. 
Surgery has been the primary intervention for her throughout her multiple 
recurrences. We would like to suggest that with a nonaggressive tumor biology and 
only locally recurrent disease, surgery can provide long-term survival for other colon 
cancer patients. Proper follow-up and patient selection will further ensure survival 
benefit from repeated surgical interventions. The role of new and active chemotherapy  
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regimens in the adjuvant setting after resection of metastases remains an interesting 
area of future investigation. 
Disclosure Statement 




Table 1. Clinical course of long-term survivor with metastatic colon cancer 
                Date  Surgery for patient  Type of 
recurrence 
Additional therapy received by patient 
                1992  1. Low anterior resection    1. 5-FU/levamisole; pelvic irradiation 
1995  2. Bilobar liver resections  Metastatic   
1999  3. En bloc abdominal wall and gastric resection  Local   
2006  4. En bloc diaphragm, stomach, liver, chest wall resection  Metastatic   
2009  5. Cardiac resection  Metastatic  2. FOLFOX 
3. FOLFOX + bevacizumab 
2010    Local  4. Bevacizumab 
                5-FU = 5-Fluorouracil; FOLFOX = 5-FU, leucovorin, oxaliplatin. 




Fig. 1. PET/CT scan showing initial myocardial recurrence (white arrow). 
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Fig. 2. PET/CT scan showing recurrence 6 months after pericardial and myocardial resection (white 
arrows). 
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